This review aims to comprehensively discuss the studies that have examined the therapeutic role of second-generation incretin analogs (semaglutide and tirzepatide) in patients with type 1 diabetes mellitus (T1D) and latent autoimmune diabetes in adults (LADA). Here, GCG is linked to type 1 diabetes mellitus.